It will be important to assess the relative efficacy of Myr-CBD7 and anti-CCL28 Ab treatments, alone and in combination, in subsequent investigations of diabetic skin wound healing in db/db mice, in larger animal models such as the high fat-fed mini-pig, as well as patients with T2DM to determine if Myr-CBD7 or anti-CCL28 Ab are effective pharmacological approaches for improving non-healing diabetic skin wounds such as DFUs. The gene discussed is CCL28; the disease is diabetes mellitus.